The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
The decision marks a key step in the centralized EU review process
The event is expected to attract more than 100 senior professionals from pharmaceutical companies, CROs, regulatory agencies, and technology organisations
Mumbai event on June 24–25 will spotlight real-world impact of pharmacovigilance beyond AI adoption
The results signal shift beyond paclitaxel-coated balloon (PCB) angioplasty in femoropopliteal artery disease
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
Subscribe To Our Newsletter & Stay Updated
